At present, the only TYK2 inhibitor studied in IBD patients is Deucravacitinib, which targets the JH2 pseudokinase regulatory domain of TYK2 and suppresses its catalytic activity through allosteric regulation, allowing for more precise regulating [16]. The gene discussed is TYK2; the disease is inflammatory bowel disease.